LXH254
Sponsors
Novartis Pharma AG, Novartis Pharmaceuticals
Conditions
BRAF V600 Colorectal CancerDifferent types of advanced cancerEGFR-mutant Non-small Cell Lung CancerMelanomaNSCLCNon-Small Cell Lung CancerOther Solid TumorsOvarian Cancer
Phase 1
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
TerminatedNCT02607813
Start: 2016-01-18End: 2022-02-19Updated: 2022-12-21
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
TerminatedNCT02974725
Start: 2017-02-24End: 2024-04-24Updated: 2025-04-13
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Active, not recruitingNCT03333343
Start: 2018-01-29End: 2026-10-05Updated: 2026-01-16
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
TerminatedNCT04294160
Start: 2020-07-22End: 2024-09-25Updated: 2025-12-24
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments
Active, not recruitingCTIS2023-508841-42-00
Start: 2019-10-30Target: 75Updated: 2025-10-28
Phase 2
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Active, not recruitingNCT04417621
Start: 2020-10-30End: 2027-02-02Updated: 2026-03-12
A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma
Active, not recruitingCTIS2024-511934-11-00
Start: 2021-04-27Target: 53Updated: 2025-12-11